Regulatory Update

Guide to Requirements for Transfer of Rights - COFEPRIS

COFEPRIS regulates the transfer of rights to ensure legal and technical compliance for medicines, medical devices, and biological products. Requirements include an application format, proof of payment, legal documentation, and a notice of operation. Transfers must be transparent, with continuous monitoring. Modifications now resolve within 24 hours instead of 3 months.

Published on:
July 19, 2024

The transfer of rights in the regulatory context is essential to ensure continuity and legality in the management of rights and obligations related to regulated products, such as medicines, medical devices and biological products, among others.

 

COFEPRIS regulates this process with the objective of guaranteeing that any transfer of rights is carried out in a transparent manner, ensuring that the new owners comply with the legal and technical requirements necessary for the proper operation and marketing of products under their responsibility. This includes evaluation of relevant documentation,verification of the transferee's suitability, and ongoing monitoring to ensure compliance with applicable regulations.

 

The requirements for the transfer of rights to medical devices are:

1. Application format

2. Proof of payment of rights

3. Accreditation of legal personality

4. Tag projects

5. Instructions/user manual project

6. Number or copy of the last registration document

7. Legal instrument that certifies the transfer

8. Letter of Representation

9. Notice of operation

10. Notify the transfer within 30 business days

 

Apart from the indicated requirements, the following must be considered:

• Application entered by assignee.

• Registration must be current.

• It should not be linked to any other procedure entered into the commission (technical/administrative modification, extension among others).

• Changes checked will be in accordance with the latest resolution.

• The Health Registry must be current. In case of presenting proof of Extension, the holder of the same must coincide with the transfer or in accordance with article 190 bis 5 of the RIS.

• Download, fill out and physically present the“Modification to the Conditions of the Health Registry” form, which must describe the conditions requested according to the modification (Says/Should say). Attach a letter with information that describes in detail the request signed by the legal representative.

• Download, fill out and present the “Medical Device Health Registry Project” format in editable digital format.

• Changes may be made in the “importer and distributor” category as long as they are reflected in your new label project. In which case, in addition to the rights transfer contract, they must present the letter(s) of representation that cover the actors in the supply chain and/or, where appropriate, a certified copy of the Letter of Representation or clarification in which A distributor has the power to appoint others as distributors. (In this case, 75% of the fee corresponding to the LFD registration will be paid).

• All information regarding the procedure must be presented in printed form.

 

The steps to follow to submit the procedures for immediate resolution modifications are:

1. Request an appointment at the Comprehensive Services Center (CIS) through the Appointment Request System to carry out COFEPRIS procedures.

2. Present the requirements indicated in the COFEPRIS Procedures and Services Agreement, in physical format.

3. After entering the procedure, the user will receive a security paper document within a maximum period of 24 hours, without the need to schedule an appointment for collection.

 

This guide was published on June 25th 2024and it starts operation until July 8, 2024, according to COFEPRIS web page.

Subscribe to newsletter
Subscribe to receive the latest blog posts to your inbox every week.
By subscribing, you agree to our Terms and Conditions.
Thank you for subscribing!
Oops! Something went wrong while submitting the form.
Read more

Latest News

Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.

Regulatory Update
January 29, 2025

Wrapping up January 2025, medical device regulatory developments include new forms for NBs in Europe, new PMS guidance in the UK, an expedited approval partnership between China and Malaysia, and warnings of supply chain disruptions for pediatric patients in the US.

Regulatory Update
January 23, 2025

Medical device regulatory developments from the US and Thailand include: final FDA guidance on modular review for premarket approval applications and humanitarian device exemptions, and new expedited regulatory routes for low-risk devices and chronic disease prevention devices in Thailand.

Regulatory Update
January 16, 2025

This week, we are reporting on medical device regulatory updates from Canada, Europe, Brazil, and China. China's NMPA released registration review timelines, clarification on MDR and IVDR vigilance terms is now available, and Health Canada updated validation rules for non-eCTD transactions.

To kick off 2025, we bring you a round up of medical device regulatory updates from across Europe and the US, including a new position paper from TEAM-NB on MDR certification processes and numerous guidance updates from the US FDA.

Contact us
Request information

Let's Talk,
Anywhere You Are.

Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.

Our closest representative will get back to you within 24 hours.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest Blog Content

Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.

Blog Article

The official IVDR transition period is here. IVDR expert Dr. Oliver Eikenberg discusses how IVD manufacturers should take action, starting with how to implement IVDR QMS requirements for the May 2025 deadline.

Kuala Lumpur Malaysia Skyline
Blog Article
Pure Global Team attends IMDEC 2024 in Malaysia

Pure Global participated in IMDEC 2024 in Kuala Lumpur to discuss the latest advancements in medical technology, regulatory efficiency, and the role of AI in transforming the industry. Highlights included updates from the Malaysian Medical Device Authority (MDA) that showcased their commitment to driving regional leadership in medical device regulation and innovation.

Pure Global 2024 Year in Review
Blog Article
Pure Global 2024 Year in Review

As 2024 comes to a close, Pure Global proudly reflects on a transformative year marked by substantial growth, cutting-edge innovation, and impactful collaborations.

Risk increases compliance chalenges under IVDR
Blog Article
What are the challenges under IVDR?

IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.